AVTX logo

AVALO THERAPEUTICS INC

AVTXNASDAQ
πŸ† #2945 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track AVTX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$391M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-86.6%
Declining
πŸ“ŠGross Margin
242.2%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
6595.8x
Expensive
Otter Score
36
Weak
No chart data available for AVTX.

Trading Snapshot

Day Range
β€”
52-Week Range
$6.53 – $24.27
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
53.6M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$59,000
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
6595.8x
EPS (TTM)
$-4.75
Dividend Yield
β€”
Dilution (1yr)
+76.8%
AVTX logo

AVALO THERAPEUTICS INC

AVTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$59Kβ–Ό βˆ’86.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–Ό βˆ’45.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$73Mβ–² +6.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$51Mβ–² +4.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.5Mβ–² +76.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13Mβ–Ό βˆ’$121M YoY
StockOtter Β· stockotter.space

About AVALO THERAPEUTICS INC

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
36/100
Analyst data unavailable.

Latest News & Updates

News unavailable.